Trazodone vs. Amitriptyline
A quick guide to how these two drugs differ (and where they overlap)
| Feature | Trazodone | Amitriptyline |
|---------|---------------|-------------------|
| Drug class | Atypical serotonin‑modulating agent (serotonin antagonist/partial agonist, re‑uptake inhibitor). | Tricyclic antidepressant (TCA) – monoamine re‑uptake inhibitor. |
| Primary indications | • Major depressive disorder (MDD)
• Insomnia (often prescribed at lower doses)
• Anxiety, PTSD, chronic pain (off‑label) | • Major depressive disorder
• Chronic neuropathic pain (e.g., diabetic neuropathy)
• Migraine prophylaxis
• Chronic tension‑type headaches
• Insomnia (especially when associated with depression) |
| Typical starting dose | • Insomnia: 25 mg at bedtime
• Depression: 150 mg daily (often split) | • Depression: 10–20 mg at bedtime
• Pain: 10–20 mg daily, titrated up to 150–300 mg/day |
| Typical maintenance dose | • Insomnia: 25–100 mg nightly (max 400 mg/day)
• Depression: 150–300 mg/day, divided | • Depression: 50–150 mg/day (max 300 mg/day)
• Pain: 50–200 mg/day |
| Onset of action | • Sedative effects: within 1–2 hrs (often used for sleep)
• Antidepressant effect: 4–6 weeks | • Antidepressant effect: 4–6 weeks (similar to many antidepressants) |
| Half‑life | ~1–2 hrs (active metabolite longer, ~10–20 hrs) | ~12 hrs (active metabolite prolongs effects) |
| Key side‑effects | • Dizziness, orthostatic hypotension (especially early)
• Priapism (rare but serious)
• Mild sedation, dry mouth, blurred vision
• Few anticholinergic effects | • Dizziness, orthostatic hypotension, sedation
• Anticholinergic: dry mouth, constipation, urinary retention, blurred vision
• Weight gain, sexual dysfunction, tremor
• Cardiac conduction changes (QT prolongation, arrhythmias) |
| Contra‑indications & cautions | • Recent MI, unstable angina, severe heart failure (QT‑prolonging)
• Concomitant MAO‑I or serotonergic drugs (serotonin syndrome risk)
• Pregnant/nursing women (limited data) | • Untreated severe cardiac disease (arrhythmias, heart block)
• Severe liver/kidney impairment (dose adjustment)
• Use with other anticholinergic drugs (risk of additive effects) |
| Drug interactions | • CYP3A4 inhibitors (e.g., ketoconazole) ↑ trazodone levels
• MAO inhibitors, SSRIs, SNRIs ↑ serotonin syndrome risk
• Alcohol → increased sedation | • CYP2C19, CYP2D6 inhibitors/inducers alter levels
• MAO inhibitors, SSRIs, SNRIs ↑ serotonin syndrome risk
• Alcohol → increased sedation and CNS depression |
| Typical clinical “use‑case” | • “Sleep‑first”: a low‑dose Trazodone (25–50 mg) for patients who sleep poorly, especially when they also have depression or anxiety.
• Depression: when a patient needs an antidepressant but wants minimal anticholinergic burden. | • “Pain‑first”: Amitriptyline at low doses (10–20 mg) for neuropathic pain or migraine, often as a daily dose at bedtime.
• Depression: when a patient tolerates or even needs the sedative and anticholinergic effects (e.g., insomnia, dry mouth). |
| Who might benefit more? | • Older adults who are prone to constipation, urinary retention, or cognitive side‑effects.
• Patients with a history of heart failure (if monitored closely). | • Patients with chronic pain or migraine.
• Those who can tolerate the anticholinergic profile (e.g., non‑elderly). |
---
Bottom‑line take‑aways
1. Both are effective antidepressants, but they act on different receptors and have distinct side‑effect spectra.
2. Trazodone is usually chosen when
* the primary need is sleep or mild anxiety.
* the patient is older or has a higher risk of anticholinergic toxicity.
* a lower sedating dose is sufficient.
3. Amitriptyline is chosen when
* the patient needs a potent antidepressant plus pain or migraine relief.
* the patient is comfortable with the anticholinergic load (often younger).
* a higher, more sustained dose is required.
4. Side‑effect management:
* With trazodone, watch for orthostatic hypotension early, and counsel patients on the rare risk of priapism.
* With amitriptyline, monitor for orthostatic hypotension, constipation, blurred vision, and weight gain, especially in older adults.
5. Drug interactions matter: both drugs share serotonin‑related risks when combined with other serotonergic agents, and both can be potentiated by alcohol or certain CYP inhibitors.
---
Quick FAQ
| Question | Short Answer |
|----------|--------------|
| Is trazodone safer in the elderly? | Generally yes, due to less anticholinergic burden, but still watch for hypotension. |
| Can trazodone be used for chronic pain? | Off‑label, but often used for neuropathic pain, though evidence is weaker than for amitriptyline. |
| Can amitriptyline be used for insomnia? | Yes, especially when insomnia co‑exists with depression, but watch for sedation and anticholinergic side‑effects. |
| What about sexual side‑effects? | Both drugs can cause sexual dysfunction, but amitriptyline’s anticholinergic effects may intensify it. |
---
Disclaimer: This overview is for educational purposes only. It should not replace individualized medical advice from a licensed healthcare professional. Always consult your prescribing clinician before starting, stopping, or changing doses of trazodone, amitriptyline, or any medication.